EKF Diagnostics Holdings PLC Director/PDMR Shareholding (5538P)
21 6월 2022 - 3:00PM
UK Regulatory
TIDMEKF
RNS Number : 5538P
EKF Diagnostics Holdings PLC
21 June 2022
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Director/PDMR Shareholding
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global
diagnostics business , announces that it has been notified that on
20 June 2022 Julian Baines, Non-Executive Deputy Chairman,
purchased a total of 11,000 ordinary shares of 1 pence each in the
Company ("Ordinary Shares") at a price of 32.596 pence per Ordinary
Share.
Following this transaction, Julian Baines' total direct and
indirect interest in the Group is 1,616,288 Ordinary Shares
representing approximately 0.36% of the Group's total issued share
capital.
The Notification of Dealing Form required in accordance with UK
MAR is set out below.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Mike Salter, CEO Tel: +44 (0)29 2071 0570
Marc Davies, CFO
Singer Capital Markets (Nominated Adviser & Tel: +44 (0)20 7496 3000
Joint Broker)
Aubrey Powell / George Tzimas
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams / Ben
Farrow
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584 391
303
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Julian Baines
------------------------------------ --------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Non-Executive Deputy Chairman
------------------------------------ --------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------------ --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name EKF Diagnostics Holdings plc
------------------------------------ --------------------------------------
b) LEI 213800DXTF3EAUK1AR05
------------------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary Shares of GBP0.01 each
financial instrument,
type of instrument
Identification code GB0031509804
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------ --------------------------------------
c) Price(s) and volume(s)
-------------------- -------------
Price(s) Volume(s)
-------------------- -------------
32.596 pence 11,000
-------------------------------------------------------------- -------------
d) Aggregated information
- Aggregated volume N/A - Single Transaction
- Price
e) Date of the transaction 20 June 2022
------------------------------------ --------------------------------------
f) Place of the transaction London Stock Exchange - AIMX
------------------------------------ --------------------------------------
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading global diagnostics business with custom
manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. EKF is focussed on the
following areas:
Point-of-Care Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in
the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated
80,000
hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than
100 countries.
Central Laboratory Clinical chemistry, Small lab analysers, Centrifuges
Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor, Glycates Albumin, Glycated Serum Protein,
Nitro-tab,
Procalcitonin
Life Sciences Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
Laboratory Services In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL
Health"), a Texas based testing laboratory certified under the Clinical Laboratory
Improvement
Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a
variety
of clinical, forensic and microbiological sample types using a range of analytical
techniques.
This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and
services from sample collection to results.
EKF's growth strategy to 2024 and beyond can be summarised
as:
-- continuing innovation in products and services in Point-of-Care,
Central Laboratory and Life Sciences leveraging new and existing
routes to market and relationships;
-- investment in expanded production and kitting capabilities to
offer a suite of diagnostic Contract Manufacturing solutions to
third party businesses;
-- expansion of CLIA Laboratories Testing offering, building on the
acquired capabilities in ADL Health; and
-- concluding complementary earnings-enhancing acquisitions with
key strategic value.
EKF will also continue to generate enhanced shareholder value
through:
-- a progressive dividend policy; and
-- its agreement with Mount Sinai Innovation Partners ("MSIP"), which
allows us advanced access to innovative commercial opportunities
and where we can build on the ongoing successes of Renalytix plc,
Verici Dx plc and Trellus Health plc.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBCGDLIXDDGDG
(END) Dow Jones Newswires
June 21, 2022 02:00 ET (06:00 GMT)
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
